Search results
Results from the WOW.Com Content Network
The drugs differ in their mechanism and side-effects. The biggest advantage is minimising the chances of resistance developing to any one agent. Also, the drugs can often be used at lower doses, reducing toxicity. [6]: 55–59 [7]: 17–18 [5]
Aprepitant has been shown to inhibit both the acute and delayed emesis induced by cytotoxic chemotherapeutic drugs by blocking substance P landing on receptors in the brains neurons. Indeed, positron emission tomography (PET) studies have shown that aprepitant can penetrate the brain and NK 1 receptors in the brain. [12]
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
Carfilzomib is derived from epoxomicin, a natural product that was shown by the laboratory of Craig Crews at Yale University to inhibit the proteasome. [8] The Crews laboratory subsequently invented a more specific derivative of epoxomicin named YU101, [9] which was licensed to Proteolix, Inc. Scientists at Proteolix invented a new, distinct compound that had potential use as a drug in humans ...
Common side effects include bone marrow suppression, vomiting, mouth ulcers, hair loss, liver problems, infections, and muscle pains. [2] Other serious side effects include future cancers, allergic reactions, and tissue death if extravasation occurs. [2] Use in pregnancy may harm the baby. [2] Dactinomycin is in the cytotoxic antibiotic family ...
Cyclophosphamide (CP), also known as cytophosphane among other names, [3] is a medication used as chemotherapy and to suppress the immune system. [4] As chemotherapy it is used to treat lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma. [4]
Bone marrow suppression is a serious side effect of chemotherapy and certain drugs affecting the immune system such as azathioprine. [2] The risk is especially high in cytotoxic chemotherapy for leukemia. In the case of non-small-cell lung cancer, myelosuppression predisposition was shown to be modulated by enhancer mutations. [3]
The most common side effects include infections, low levels of white blood cells, headache, cough, nausea (feeling sick), vomiting, diarrhea, constipation, tiredness, hair loss and rash. [ 5 ] Ribociclib was approved for medical use in the United States in March 2017, [ 7 ] [ 8 ] in the European Union in August 2017, [ 5 ] [ 9 ] and in the ...